Chloroquine Inhibitor

Chloroquine Inhibitor [NBP2-29386] - TLR9/NF-kB/SEAPorter™ HEK 293 and TLR2/NF-kB/SEAPorter™ HEK 293 cells were plated in 96-well plates at 5x10^4 cells/well for 16 h. Cells were preincubated with different concentrations of chloroquine (0.05, 0.1, 0.5, 1, 5 and 10 uM) for 30 min. Cell were then stimulated with 10ug/ml CpG [A] or 20 ng/ml MALP-2 [B] for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter™ Assay Kit.

Chloroquine Inhibitor [NBP2-29386] - TLR9/NF-kB/SEAPorter™ HEK 293 cells were plated in 96-well plates at 5x10^4 cells/well for 16 h. Cells were preincubated with various concentrations of chloroquine for 30 min, followed by stimulation with 10 ug/ml CpG for 24 h. SEAP was analyzed using SEAPorter™ Assay Kit. Dose-responsive percent inhibition of each sample well was calculated to yield the chloroquine IC50 value.

Chloroquine Inhibitor [NBP2-29386]

• Applications: B/N

Chloroquine Inhibitor Summary

• Immunogen: CAS Number 50-63-5
  Empirical Formula (Hill Notation) C18H26ClN3. 2H3PO4
  Molecular Weight 515.86

Applications/Dilutions

• Dilutions:
  • Block/Neutralize
• Application Notes: DNA intercalator. Also used to increase transfection efficiency. Use in blocking/ neutralizing reported in scientific literature (PMID: 30239551).

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: Solubility:Deionized water
  Form : White Solid (Powder)

Background

Chloroquine is a weak base which can partition into acidic vesicles such as endosomes and lysosomes, resulting in inhibition of endosomal acidification and lysosomal enzyme activity. Because acidic pH of endosomes is a prerequisite of endosomal TLR activation, chloroquine can serve as an antagonist for endosomal TLRs. Chloroquine and its analog quinacrine are also known to act as therapeutic agents for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, of which therapeutic activity is due to suppression of TLR9 activity as shown by researchers.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Inhibitors are guaranteed for 1 year from date of receipt.

Publications for Chloroquine Inhibitor (NBP2-29386)(4)

Publications using NBP2-29386

• Lin RC, Chao YY, Su MT et al. Upregulation of miR-20b-5p inhibits trophoblast invasion by blocking autophagy in recurrent miscarriage Cellular signalling 2023-10-21 [PMID: 37871665]
• Chao Y, Huang B, Peng I et al. ATM- and ATR-Induced Primary Ciliogenesis Promotes Cisplatin Resistance in Pancreatic Ductal Adenocarcinoma Research Square 2021-12-02 [PMID: 36251015]
• Niu Z, Tang W, Liu T et al. Cell-free DNA derived from cancer cells facilitates tumor malignancy through Toll-like receptor 9 signaling-triggered interleukin-8 secretion in colorectal cancer. Acta Biochim. Biophys. Sin. (Shanghai) 2018-09-15 [PMID: 30239551] (B/N)
• Syu J. S, Baba T, et al. Lysosomal activity maintains glycolysis and cyclin E1 expression by mediating Ad4BP/SF-1 stability for proper steroidogenic cell growth. Sci Rep 2017-03-21 [PMID: 28325912]

FAQs for Chloroquine Inhibitor (NBP2-29386). (Showing 1 - 1 of 1 FAQs).

1. I am looking to test the effect of blocking the TLR9 on animal model (pigs with sternotomy) by chloroquine, Can you kindly advice me regarding whether is it possible to try it in vivo for approximatley 50kg animal and what is the optimum dose for better effect aftrer few hours of adminstration of the dose?
   • We evaluate Chloroquinone on TLR9 Stably Transfected cell lines, but have not evaluated Chloroquine in animals. However, Chloroquine has been widely published for in vivo use. I would encourage you to review the scientific literature regarding the use of Chloroquine in animals for inhibiting TLR9, for example please seee this LINK.